-
Thematic Analysis
Power M&A Deals 2023 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in 2023 in the Power Sector
-
Product Insights
Roseberry Inv – Oca Verde Residential Community – Leinster
Equip yourself with the essential tools needed to make informed and profitable decisions with our Roseberry Inv - Oca Verde Residential Community - Leinster report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Sector Analysis
Uruguay Cards and Payments – Opportunities and Risks to 2027
Uruguay Cards and Payments Market Overview The Uruguay cards and payments market size was $18.6 billion in 2023. The market will register a CAGR of more than 13% during 2023-2027. The government’s financial inclusion initiatives have allowed the Uruguayans to gradually adopt electronic payment methods over 2019-2023. Uruguay Cards and Payments Market Outlook, 2023-2027 ($ Billion) Buy the Full Report to Gain More Information on the Uruguay Cards and Payments Market Forecast Download a Free Report Sample The Uruguay cards...
-
Company Profile
Intercept Pharmaceuticals Inc – Company Profile
Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops, and commercializes treatments for non-viral, progressive liver diseases. It develops products using proprietary bile acid chemistry. The company’s lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor. The company is advancing OCA for the treatment of various other liver diseases. The company harnesses its proprietary bile acid chemistry to develop innovative drugs. It is also advancing INT-787, an FXR...
Add to Basket -
Product Insights
Net Present Value Model: Harnal/Omnic
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Harnal/Omnic Drug Details Tamsulosin hydrochloride (Secotex...
-
Sector Analysis
Payments Landscape in Uruguay: Opportunities and Risks to 2021
GlobalData’s "Payments Landscape in Uruguay: Opportunities and Risks to 2021", report provides detailed analysis of market trends in the Uruguayan cards and payments industry. It provides values and volumes for a number of key performance indicators in the industry, including credit transfers, direct debit, payment cards, and cheques during the review-period (2013-17). The report also analyzes various payment card markets operating in the industry and provides detailed information on the number of cards in circulation, transaction values and volumes during...
-
Product Insights
Fibrosis Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Fibrosis Global Clinical Trials Review, H2, 2017" provides an overview of Fibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...